~~<i id='104F5B645C'><strike id='104F5B645C'><tt id='104F5B645C'><pre id='104F5B645C'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：focus 2025-09-06 06:00:36 Page View：24

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why Congress must ban federal programs from using QALYs
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

knowledge

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Israel withdraws forces after 2

2:45PeoplestandbyrubbleandtheremainsofadestroyedvehicleoutsideamosqueintheoccupiedWestBankcityofJeni

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

3:21SupremeCourtjusticesposefortheirgroupportraitattheSupremeCourtinWashington,Oct.7,2022.EvelynHock